Company
Neuronetics
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
11
510(k), De Novo and PMA
Device trials
12
As lead sponsor, any status
Adverse event reports
31
Received Nov 1, 2025 to Nov 19, 2026
Recall records
2
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
STIM
Nasdaq · Neuronetics, Inc.
Public float
$129M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$149M
Fiscal year ending Dec 31, 2025
Net income
-$39.0M
Fiscal year ending Dec 31, 2025
R&D spending
$6.6M
Fiscal year ending Dec 31, 2025
Cash
$22.1M
As of Sep 30, 2026
Long-term debt
$61.8M
As of Sep 30, 2026
Shares outstanding
77.7M
As of Oct 28, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | – | $10.0M | – |
| 2024 | – | – | $57.5M | – |
| 2023 | – | – | $25.0M | – |
| 2021 | – | $81.0M | – | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Jun 1, 2017 | Equity | $15.0M | $15.0M | 22 | Rule 506(b) | Form D ↗Jun 13, 2017 |
| Apr 24, 2015 | Equity | $34.3M | $34.3M | 23 | Rule 506(b) | Form D ↗May 7, 2015 |
| Nov 21, 2014 | Options or warrants | $9.1M | $15.0M | 23 | Rule 506(b) | Form D ↗Dec 3, 2014 |
| Dec 20, 2012 | Options or warrants | $272K | $272K | 1 | Rule 506 | Form D ↗Jan 3, 2013 |
| May 13, 2011 | Equity | $30.0M | $30.0M | 22 | Rule 506 | Form D ↗May 23, 2011 |
| Aug 20, 2009 | Equity | $30.0M | $30.5M | 17 | Rule 506 | Form D ↗Aug 21, 2009 |
Company details
From the company's latest Form D.
- Legal name
- Neuronetics, Inc.
- Headquarters
- Malvern, Pennsylvania
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1227636 ↗
Executives, directors and promoters
As listed on the latest Form D.
- Cassie HallbergExecutive Officer
- Anthony PuiExecutive Officer
- Christopher ThatcherExecutive Officer, Director
- Greg HarperExecutive Officer
- Brian FarleyDirector
- Stephen CampeDirector
- Peter DonatoExecutive Officer
- Wilfred JaegerDirector
- Ron HuntDirector
- Steve MacKinnonExecutive Officer
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
The investor database is part of the paid tier
It is included for signed-in readers who have credit, along with the daily news digest. Credit is also what pays for AI device summaries.
Latest FDA decisions
The 8 newest of 11 since 2015.
K231926 · Decided Mar 22, 2024 · 266 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
K233621 · Decided Dec 13, 2023 · 30 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
K231350 · Decided Jun 8, 2023 · 30 days after receipt
Device type: Transcranial Magnetic Stimulation System For Obsessive-Compulsive Disorder (QCI) · Neurology & Neurosurgery
K230029 · Decided Apr 4, 2023 · 90 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
K222230 · Decided Aug 24, 2022 · 30 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
K220127 · Decided Jul 15, 2022 · 178 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
K212289 · Decided May 6, 2022 · 289 days after receipt
Device type: Transcranial Magnetic Stimulation System For Obsessive-Compulsive Disorder (QCI) · Neurology & Neurosurgery
K213543 · Decided Dec 10, 2021 · 32 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Symptom Evaluation Following Repetitive Transcranial Magnetic StimulationActive, not recruiting
NCT06429748 · 20 participants · Start May 15, 2024 · Primary completion Apr 29, 2025
Device: rTMS · For: Neurologic Symptoms
Sites: Charlotte, North Carolina
- Accelerated TMS for MDDActive, not recruiting
NCT07147218 · 50 participants · Start Aug 21, 2025 · Primary completion Dec 31, 2027
Device: TMS · For: Major Depressive Disorder
Sites: New York, New York; Charlotte, North Carolina; Spokane, Washington
NCT06997549 · 12,000 participants (planned) · Start May 15, 2025 · Primary completion Dec 2035
Device: Patients treated with NeuroStar TMS · For: Depression; OCD; Anxiety Depression
Sites: Malvern, Pennsylvania
NCT06917339 · 156,000 participants (planned) · Start Feb 25, 2025 · Primary completion Dec 2035
Device: NeuroStar Advanced TMS Therapy System · For: Depression; Obsessive-Compulsive Disorder; Anxiety Depression
Sites: Malvern, Pennsylvania
- Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed AdolescentsPivotal-lookingCompleted
NCT02586688 · 112 participants · Start Oct 2015 · Primary completion Jan 2018
Device: Active NeuroStar® Transcranial Magnetic Stimulation (TMS); Sham NeuroStar® Transcranial Magnetic Stimulation (TMS) · For: Major Depressive Disorder
Sites: Dothan, Alabama; Los Angeles, California; Palo Alto, California · 13 sites in all
NCT01415154 · 67 participants · Start Aug 2011 · Primary completion Sep 2013
Device: NeuroStar TMS · For: Major Depressive Disorder
Sites: Chicago, Illinois; Baltimore, Maryland; Lincoln, Nebraska · 6 sites in all
Reports received
31
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
1
3.2% of reports
Injury reports
30
97% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 1 | 0 | 0 |
| Jan 24 | 0 | 3 | 0 | 0 |
| Feb 24 | 0 | 2 | 0 | 0 |
| Mar 24 | 0 | 7 | 0 | 0 |
| Apr 24 | 0 | 4 | 0 | 0 |
| May 24 | 0 | 1 | 0 | 0 |
| Jun 24 | 0 | 5 | 0 | 0 |
| Jul 24 | 0 | 1 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 2 | 0 | 0 |
| Oct 24 | 0 | 1 | 0 | 0 |
| Nov 24 | 0 | 8 | 0 | 0 |
| Dec 24 | 0 | 2 | 0 | 0 |
| Jan 25 | 0 | 2 | 0 | 0 |
| Feb 25 | 0 | 3 | 0 | 0 |
| Mar 25 | 0 | 1 | 0 | 0 |
| Apr 25 | 0 | 6 | 0 | 0 |
| May 25 | 0 | 21 | 0 | 0 |
| Jun 25 | 0 | 8 | 0 | 0 |
| Jul 25 | 0 | 6 | 0 | 0 |
| Aug 25 | 0 | 4 | 0 | 0 |
| Sep 25 | 0 | 10 | 0 | 0 |
| Oct 25 | 0 | 2 | 0 | 0 |
| Nov 25 | 0 | 2 | 0 | 0 |
| Dec 25 | 0 | 1 | 0 | 0 |
| Jan 26 | 0 | 2 | 0 | 0 |
| Feb 26 | 0 | 5 | 0 | 0 |
| Mar 26 | 0 | 5 | 0 | 0 |
| Apr 26 | 0 | 4 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 1 | 1 | 0 | 0 |
| Jul 26 | 0 | 5 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 4 | 0 | 0 |
| Oct 26 | 0 | 1 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0142-2027 · Started Aug 24, 2026 · Posted by FDA Oct 9, 2026
Reason given: Cables are not in conformance with the product specifications required in the production of the HP Coil Assembly.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Transcranial Magnetic Stimulator (OBP)
Z-1421-2009 · Started Mar 16, 2009 · Posted by FDA May 27, 2009
Reason given: SenStar Treatment Link may have an open circuit that during use with the NeuroStar TMS Therapy system may cause arcing and heat damage to the SenStar and/or treatment coil. Heating of the SenStar during use has a potential risk of minor scalp burn to patients.
Cause as FDA categorized it: Process control · Device type: Transcranial Magnetic Stimulator (OBP)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.